The design and development of a multicentric protocol to investigate the impact of adjunctive doxycycline on the management of peripheral lymphoedema caused by lymphatic filariasis and podoconiosis.


Journal

Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774

Informations de publication

Date de publication:
30 Mar 2020
Historique:
received: 27 11 2019
accepted: 16 03 2020
entrez: 2 4 2020
pubmed: 2 4 2020
medline: 24 11 2020
Statut: epublish

Résumé

As new lymphatic filariasis infections are eliminated through mass chemotherapy, previously affected individuals are left with the sequellae, especially chronic progressive lymphoedema. Currently this is managed by careful attention to limb hygiene to prevent infection. Studies over the past 15 years have suggested that the incorporation of doxycycline treatment may arrest or even reverse progression of lymphoedema. Most of this work has been observational or based on small studies, and if this intervention is effective, studies need to be conducted on a larger scale and under diverse geographical and social conditions before it can be incorporated into treatment policy. The double-blind, placebo-controlled study was designed to investigate the impact of six weeks treatment with doxycycline added to standard limb hygiene on early stage filarial lymphoedema in five sites in Africa and the Indian subcontinent. One site in Cameroon is selected for studying lymphoedema in podoconiosis. Each site was individually powered with the potential to undertake a meta-analysis on completion. Evaluation methods followed those used in Ghana in 2012 with additions resulting from advances in technology. The details of the core protocol and how it was varied to take account of differing situations at each of the sites are provided. The study will enrol up to 1800 patients and will complete in mid-2021. This paper provides details of what challenges were faced during its development and discusses the issues and how they were resolved. In particular, the reasons for inclusion of new technology and the problems encountered with the supply of drugs for the studies are described in detail. By making these details available, it is hoped that the study protocol will help others interested in improving treatment for filarial lymphoedema in the design of future studies. Trial registration India: Clintrials.gov. NCT02929121 registered 10 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT02929121 Mali: Clintrials.gov. NCT02927496 registered 7 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT0292749 Sri Lanka: Clintrials.gov. NCT02929134 registered 10 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT02929134 Ghana: ISRCTN. 14042737 registered 10 July 2017: https://doi.org/10.1186/ISRCTN14042737 Tanzania: ISRCTN. 65756724 registered 21 July 2017: https://doi.org/10.1186/ISRCTN65756724 Cameroon: ISRCTN. 1181662 registered 25 July 2017: https://doi.org/10.1186/ISRCTN11881662.

Sections du résumé

BACKGROUND BACKGROUND
As new lymphatic filariasis infections are eliminated through mass chemotherapy, previously affected individuals are left with the sequellae, especially chronic progressive lymphoedema. Currently this is managed by careful attention to limb hygiene to prevent infection. Studies over the past 15 years have suggested that the incorporation of doxycycline treatment may arrest or even reverse progression of lymphoedema. Most of this work has been observational or based on small studies, and if this intervention is effective, studies need to be conducted on a larger scale and under diverse geographical and social conditions before it can be incorporated into treatment policy.
METHODS/DESIGN METHODS
The double-blind, placebo-controlled study was designed to investigate the impact of six weeks treatment with doxycycline added to standard limb hygiene on early stage filarial lymphoedema in five sites in Africa and the Indian subcontinent. One site in Cameroon is selected for studying lymphoedema in podoconiosis. Each site was individually powered with the potential to undertake a meta-analysis on completion. Evaluation methods followed those used in Ghana in 2012 with additions resulting from advances in technology. The details of the core protocol and how it was varied to take account of differing situations at each of the sites are provided. The study will enrol up to 1800 patients and will complete in mid-2021.
CONCLUSIONS CONCLUSIONS
This paper provides details of what challenges were faced during its development and discusses the issues and how they were resolved. In particular, the reasons for inclusion of new technology and the problems encountered with the supply of drugs for the studies are described in detail. By making these details available, it is hoped that the study protocol will help others interested in improving treatment for filarial lymphoedema in the design of future studies. Trial registration India: Clintrials.gov. NCT02929121 registered 10 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT02929121 Mali: Clintrials.gov. NCT02927496 registered 7 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT0292749 Sri Lanka: Clintrials.gov. NCT02929134 registered 10 Oct 2016: https://clinicaltrials.gov/ct2/show/NCT02929134 Ghana: ISRCTN. 14042737 registered 10 July 2017: https://doi.org/10.1186/ISRCTN14042737 Tanzania: ISRCTN. 65756724 registered 21 July 2017: https://doi.org/10.1186/ISRCTN65756724 Cameroon: ISRCTN. 1181662 registered 25 July 2017: https://doi.org/10.1186/ISRCTN11881662.

Identifiants

pubmed: 32228663
doi: 10.1186/s13071-020-04024-2
pii: 10.1186/s13071-020-04024-2
pmc: PMC7106687
doi:

Substances chimiques

Doxycycline N12000U13O

Banques de données

ClinicalTrials.gov
['NCT02929121', 'NCT02927496', 'NCT02929134']
ISRCTN
['ISRCTN14042737', 'ISRCTN65756724', 'ISRCTN1181662']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

155

Subventions

Organisme : NIAID NIH HHS
ID : K08 AI121422
Pays : United States
Organisme : USAID
ID : AID-OAA-G-14-00008
Organisme : Bundesministerium für Bildung und Forschung
ID : 7694

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2012 Sep;55(5):621-30
pubmed: 22610930
PLoS Negl Trop Dis. 2015 Oct 23;9(10):e0004171
pubmed: 26496129
Bull World Health Organ. 2010 Nov 1;88(11):815-23
pubmed: 21076562
Am J Trop Med Hyg. 2009 Oct;81(4):702-11
pubmed: 19815891
Antimicrob Agents Chemother. 2003 Nov;47(11):3630-3
pubmed: 14576133
Am J Trop Med Hyg. 2017 Dec;97(6):1836-1842
pubmed: 29141750
Wkly Epidemiol Rec. 2014 Sep 19;89(38):409-18
pubmed: 25243263
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
PLoS Negl Trop Dis. 2014 Nov 20;8(11):e3319
pubmed: 25412180
Trans R Soc Trop Med Hyg. 2018 Sep 1;112(9):417-418
pubmed: 30239941
PLoS Pathog. 2006 Sep;2(9):e92
pubmed: 17044733
Trop Med Int Health. 2008 Oct;13(10):1277-83
pubmed: 18721188
Trop Med Infect Dis. 2019 Jul 09;4(3):
pubmed: 31323942

Auteurs

John Horton (J)

Tropical Projects, 24 The Paddock, Hitchin, UK. hedgepigs@aol.com.

Ute Klarmann-Schulz (U)

Institute for Medical Microbiology, Immunology and Parasitology (IMMIP), German Centre for Infection Research (DZIF), Bonn-Cologne Site, University Hospital Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.

Mariana Stephens (M)

Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, GA, USA.

Philip J Budge (PJ)

Washington University School of Medicine, St. Louis, MO, USA.

Yaya Coulibaly (Y)

Filariasis Research Unit, International Center for Excellence in Research, ICER-Mali, Bamako, Mali.

Alex Debrah (A)

Faculty of Allied Health Sciences, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana.

Linda Batsa Debrah (LB)

Department of Microbiology, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana.

Suma Krishnasastry (S)

Filariasis Research Unit, Govt. T D Medical College, Kerala, 699005, India.

Upendo Mwingira (U)

National Institute for Medical Research, Dar es Salaam, Tanzania.

Abdallah Ngenya (A)

National Institute for Medical Research, Dar es Salaam, Tanzania.

Samuel Wanji (S)

Department of Microbiology and Parasitology, University of Buea, Buea, SW State, Cameroon.

Mirani Weerasooriya (M)

Filariasis Research Training and Services Unit (FRTSU), Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.

Channa Yahathugoda (C)

Filariasis Research Training and Services Unit (FRTSU), Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.

Inge Kroidl (I)

Division of Infectious Diseases and Tropical Medicine, University Hospital of the University of Munich (LMU), Munich, Germany.

Drew Deathe (D)

Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, GA, USA.

Andrew Majewski (A)

Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, GA, USA.

Sarah Sullivan (S)

Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, GA, USA.

Charles Mackenzie (C)

Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, GA, USA.

Thomas B Nutman (TB)

Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.

Joseph P Shott (JP)

Division of Neglected Tropical Diseases, US Agency for International Development, 1300 Pennsylvania Ave NW, Washington, DC, USA.

Gary Weil (G)

Washington University School of Medicine, St. Louis, MO, USA.

Eric Ottesen (E)

Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, GA, USA.

Achim Hoerauf (A)

Institute for Medical Microbiology, Immunology and Parasitology (IMMIP), German Centre for Infection Research (DZIF), Bonn-Cologne Site, University Hospital Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH